Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have completed the 2-year treatment and observation period in the Phase 3/4 Zemaira® CE1226_4001 study (NCT00261833) and are willing to sign informed consent~* Males, and non-pregnant, non-lactating females, whose screening pregnancy test is negative and who are using contraceptive methods deemed reliable by the investigator~Exclusion Criteria:~* Individuals residing in the US~* Current evidence of alcohol abuse or abuse of drugs such as barbiturates, benzodiazepines, amphetamines, cocaine, opioids, and cannabinoids~* History of allergy, anaphylactic reaction, or severe systemic response to human plasma derived products, or known mannitol hypersensitivity, or history of prior adverse reaction to mannitol~* Current tobacco smoker (smoking must be discontinued for at least 6 months prior to study participation)~* Conditions or behaviors that interfere with attending scheduled study visits in the opinion of the investigator~* History of non-compliance~* Administration of any other experimental new drug or participation in an investigation of a marketed product~* Inability to perform necessary study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zemaira® (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).